Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each), NDC 69097-032-74; Inner carton: 28 capsules (4 blisters of 7 capsules), NDC 69097-032-56; Foil blister: NDC 69097-032-17
Published March 11, 2026 · Recall initiated: February 18, 2026
Summary
FDA records drug Class III recall D-0382-2026, published March 11, 2026 and initiated February 18, 2026. Recalling firm: Cipla USA, Inc.; Status: Ongoing; Reported quantity: 164 cartons; Lot: Lot #: 5GJ0223, Exp 04/30/2027. Class III means the product is not likely to cause adverse health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
What to do
Voluntary: Firm initiated · Letter
Get an email if NILOTINIB has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- NILOTINIB
- Manufacturer
- Cipla USA, Inc.
- Distributor
- U.S.A. Nationwide
- Lot
- Lot #: 5GJ0223, Exp 04/30/2027
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDANilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa,March 11, 2026
- FDAMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged andMarch 11, 2026
- FDASemaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c)March 11, 2026
- FDAProduct label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: RisingMarch 11, 2026
- FDASemaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c)March 11, 2026
- FDAFIVE-STAR, VASOCAINE Spray, (Lidocaine HCl 4%, Racepinephrine HCl 0.01%), 4oz bottles, Distributed By: DermalMarch 11, 2026
Questions about this recall
Was Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each), NDC 69097-032-74; Inner carton: 28 capsules (4 blisters of 7 capsules), NDC 69097-032-56; Foil blister: NDC 69097-032-17 recalled?
Yes. FDA published recall D-0382-2026 on March 11, 2026. Reported hazard: Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: NILOTINIB.